Target Price | $582.51 |
Price | $557.95 |
Potential | 4.40% |
Number of Estimates | 25 |
25 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $582.51. This is 4.40% higher than the current stock price. The highest price target is $675.00 20.98% , the lowest is $470.00 15.76% . | |
A rating was issued by 34 analysts: 20 Analysts recommend Intuitive Surgical to buy, 13 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 4.40% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
26 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $9.7b . This is 10.91% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.8b 12.81% , the lowest is $9.5b 8.99% .
This results in the following potential growth metrics:
2024 | $8.4b | 17.24% |
---|---|---|
2025 | $9.7b | 15.73% |
2026 | $11.2b | 15.41% |
2027 | $12.9b | 15.48% |
2028 | $14.6b | 13.36% |
2029 | $16.0b | 9.26% |
21 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $3.9b . This is 59.76% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.8b 95.52% , the lowest is $3.3b 34.70% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $2.8b | 59.71% |
---|---|---|
2025 | $3.9b | 38.32% |
2026 | $4.5b | 15.46% |
2027 | $5.4b | 19.40% |
2028 | $6.4b | 17.23% |
2029 | $7.2b | 12.62% |
2024 | 34.11% | 36.23% |
---|---|---|
2025 | 40.76% | 19.51% |
2026 | 40.78% | 0.05% |
2027 | 42.17% | 3.41% |
2028 | 43.61% | 3.41% |
2029 | 44.95% | 3.07% |
11 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.5b . This is 0.52% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 8.12% , the lowest is $2.3b 5.92% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.3b | 29.18% |
---|---|---|
2025 | $2.5b | 6.05% |
2026 | $2.9b | 19.64% |
2027 | $3.5b | 17.98% |
2028 | $4.1b | 17.65% |
2024 | 27.81% | 10.18% |
---|---|---|
2025 | 25.48% | 8.37% |
2026 | 26.42% | 3.69% |
2027 | 26.99% | 2.16% |
2028 | 28.01% | 3.78% |
11 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $6.87 . This is 1.18% higher than earnings per share in the financial year 2024. The highest EPS forecast is $7.47 10.01% , the lowest is $6.50 4.27% .
This results in the following potential growth metrics and future valuations:
2024 | $6.42 | 27.63% |
---|---|---|
2025 | $6.87 | 7.01% |
2026 | $8.22 | 19.65% |
2027 | $9.70 | 18.00% |
2028 | $11.41 | 17.63% |
Current | 82.17 | 12.60% |
---|---|---|
2025 | 80.29 | 1.21% |
2026 | 67.11 | 16.42% |
2027 | 56.89 | 15.23% |
2028 | 48.35 | 15.01% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 19.98 and an P/S ratio of 20.46 .
This results in the following potential growth metrics and future valuations:
Current | 22.41 | 19.08% |
---|---|---|
2025 | 19.98 | 9.82% |
2026 | 17.32 | 13.35% |
2027 | 14.99 | 13.41% |
2028 | 13.23 | 11.79% |
2029 | 12.11 | 8.47% |
Current | 22.95 | 17.74% |
---|---|---|
2025 | 20.46 | 9.84% |
2026 | 17.73 | 13.35% |
2027 | 15.35 | 13.41% |
2028 | 13.54 | 11.79% |
2029 | 12.40 | 8.47% |
Intuitive Surgical...
Analyst | Rating | Action | Date |
---|---|---|---|
Citigroup |
Buy
➜
Buy
|
Unchanged | May 22 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 24 2025 |
Baird |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 23 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | Apr 23 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Apr 23 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Citigroup:
Buy
➜
Buy
|
May 22 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 24 2025 |
Unchanged
Baird:
Outperform
➜
Outperform
|
Apr 23 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 23 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 23 2025 |
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
Apr 23 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Apr 23 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.